Styker boosts guidance — but perhaps not enough — after Street-beating Q1

02 May 2023
www.massdevice.com
Investors sent SYK shares down more than 4% to $286 apiece in after-hours trading this evening. The orthopedic and surgical device giant earned $592 million, or $1.54 per share, off of $4.78 billion for the quarter ended March 31, 2023. The bottom line was up 83.3%, and the top line was up 11.8% compared with the same quarter a year ago. Adjusted to exclude one-time items, Stryker’s EPS was $2.14. The result was 14¢ ahead of The Street, where the analyst consensus was EPS of $2 and revenue of $4.56 billion. “Demand remains strong for our products, and supply chain pressures are gradually improving,” CEO Kevin Lobo said in a news release. Stryker upped its 2023 guidance to 8–9% sales growth and adjusted EPS  of $10.05–10.25. According to BTIG analysts, the whisper estimates on The Street predicted 13% organic growth. During this evening’s earnings call, Lobo defended the guidance raise. Analysts questioned whether it was too cautious given the strong early-year momentum. “We are not completely out of the woods on supply chain issues, which can cause uncertainty. Launches have to actually occur on time and be able to deliver what we hope they can deliver,” Lobo said. BTIG analysts said Lobo faced a high bar, with whisper estimates looking for roughly 13% organic growth. They kept their Buy rating on SYK shares Stryler officials also said they were unworried about health providers increasingly deciding to rent Stryker’s Mako robotic surgery systems versus buying them. Lobo later added that Mako rentals often convert within a year or two into a purchase. “Honestly, rentals have been part of our plan. And so as we look at sort of how we’re attacking the market, we’re focused on placements,” said Stryker CFO Glenn Boehnlein.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.